Skip to main content

Month: February 2026

Cerrado Gold Recognized as Top 50 TSX Venture Exchange Company

TSX Venture 50 BadgeTSX Venture 50 Badge329% share price appreciation in 2025 Company expects strong shareholder value drivers in 2026TORONTO, Feb. 18, 2026 (GLOBE NEWSWIRE) — Cerrado Gold Inc. [TSX.V: CERT][OTCQX: CRDOF] (“Cerrado” or the “Company”) is pleased to announce that it has been recognized as one of the 2026 top 50 performers on the TSX Venture Exchange (“TSXV”), based on an outstanding 329% (C$1.61) share price appreciation and 460% (C$183mm) market capitalization growth for the period of January 1, 2025 to December 31, 2025. The company ranked 22nd out of the top 50 performing companies, including 1,600 TSXV issuers, according to the TSX/TSXV Market Intelligence Group. The TSX Venture 50 is an annual ranking of the top-performing companies on the TSXV over the past year, based on three equally weighted...

Continue reading

Streamex Announces Official Launch Date of GLDY, a Yield Bearing Gold-Backed Tokenized Security

GLDY will launch February 25, 2026, introducing an institutional-grade yield generating gold backed asset WINTER PARK, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex”) (NASDAQ: STEX), a commodity focused real-world asset tokenization company, today announced the official launch date of GLDY, a gold-backed, tokenized security designed to provide exposure to physical gold while generating yield. GLDY is scheduled to launch on February 25, 2026. Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said: “For decades, investors have accepted that holding gold comes with a cost, whether through storage, insurance, or ETF management fees. GLDY fundamentally changes that equation. After more than three and a half years of building the infrastructure, we’ve created a product that allows investors to maintain...

Continue reading

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025

Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio update. Audio WebcastThe call will be...

Continue reading

The Vita Coco Company Reports Fourth Quarter and Full Year 2025 Financial Results

Full Year Net Sales were $610 million, up 18%, driven by strong Vita Coco Coconut Water growth of 26% Full Year Net Income Increased $15 million to $71 million and Non-GAAP Adjusted EBITDA1 Increased $14 million to $98 million For Fiscal Year 2026, Expect Net Sales between $680 million and $700 million and Adjusted EBITDA2 between $122 million and $128 million NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Compared to Prior Year PeriodNet sales were $128 million, up $0.5 million in the fourth quarter, resulting in full year net sales of $610 million, an increase...

Continue reading

KP Tissue Releases Fourth Quarter and Full Year 2025 Financial Results

Strong financial and operational performance in 2025 MISSISSAUGA, Ontario, Feb. 18, 2026 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2025 and full year 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.1% interest in Kruger Products. Kruger Products Q4 2025 Business and Financial HighlightsRevenue was $560.1 million in Q4 2025 compared to $539.6 million in Q4 2024, an increase of $20.5 million or 3.8%. Adjusted...

Continue reading

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

— Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 — — Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY–         — Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 — — $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 — NAARDEN, the Netherlands and MIAMI, Feb. 18, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein...

Continue reading

ParaZero Achieves Extraordinary Results in Intercepting High Speed Hostile Drones at High Speed of 70 mph

Kfar Saba, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, proudly announces outstanding results from an internal live testing of its DefendAir™ system. In the trial, DefendAir successfully intercepted a fast-moving drone traveling at 70 mph using its patented net-launching technology. This marks the first-ever successful net-based interception of a drone at such high speed by ParaZero. The system demonstrated its capability for real-time, on-the-move protection against rapidly approaching aerial threats. The test simulated a realistic combat scenario of a hostile drone closing in at high speed on ground forces. The achievement...

Continue reading

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$100,000 (the “Private Placement”). The Private Placement consisted of the issuance and sale of 4,000,000 units of the Company (the “Units”) at a price of C$0.025 per Unit. Each Unit issued pursuant to the Private Placement consists of one Class A common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company...

Continue reading

Verisk Reports Fourth-Quarter and Full-Year 2025 Financial Results

Fourth Quarter HighlightsRevenue was $779 million, up 5.9%, and up 5.2% on an organic constant currency (OCC) basis, a non-GAAP measure. Net income was $197 million, down 6.2% due to gains recognized in the prior year. Adjusted EBITDA, a non-GAAP measure, was $437 million, up 9.8%, and up 6.2% on an OCC basis. Diluted GAAP earnings per share was $1.42, down 1.4%. Diluted adjusted EPS, a non-GAAP measure, was $1.82, up 13.0%. Net cash provided by operating activities was $343 million, up 34.4% and free cash flow, a non-GAAP measure, was $276 million, up 38.0%. We paid a cash dividend of 45 cents per share on December 31, 2025. Our Board of Directors approved a cash dividend of 50 cents per share payable on March 31, 2026, an increase of 11%.  Our Board approved an increase to the share repurchase authorization to $2.5 billion in total.Full-Year...

Continue reading

Mister Car Wash Announces Fourth Quarter and Full Year 2025 Results

Net revenues increased 4%Comparable-store sales increased 1.6%Unlimited Wash Club® (“UWC”) memberships increased 7%Opened 16 new greenfield locations TUCSON, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) — Mister Car Wash, Inc. (the “Company”) (Nasdaq: MCW), the nation’s leading car wash brand, today announced its financial results for the quarter and year ended December 31, 2025. “We delivered a strong finish to 2025, highlighted by solid membership growth of 7% in the fourth quarter to end the year with nearly 2.3 million members, positioning us exceptionally well as we enter 2026,” said John Lai, Chairperson and CEO of Mister Car Wash. “In addition, we surpassed $1 billion in revenue for the full year for the first time in our history. These results reflect the consistency of our operating model, the strength of our customer value proposition,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.